Viatris patents expiration
1. Geodon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5312925 | VIATRIS | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6245766 | VIATRIS | Method of treating psychiatric conditions |
Dec, 2018
(5 years ago) | |
| US6150366 | VIATRIS | Ziprasidone formulations |
May, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-232) | Jan 28, 2025 |
| New Indication(I-615) | Nov 20, 2012 |
Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 February, 2001
Treatment: Treatment of bipolar disorder
Dosage: CAPSULE;ORAL
GEODON family patents
2. Geodon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6110918 | VIATRIS | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
Mar, 2017
(7 years ago) | |
| US6399777 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(7 years ago) | |
| US6232304 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(7 years ago) | |
Drugs and Companies using ZIPRASIDONE MESYLATE ingredient
Market Authorisation Date: 21 June, 2002
Treatment: NA
Dosage: POWDER;INTRAMUSCULAR
GEODON family patents
3. Neurontin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6054482 | VIATRIS | Lactam-free amino acids |
Apr, 2017
(7 years ago) | |
|
US6054482 (Pediatric) | VIATRIS | Lactam-free amino acids |
Oct, 2017
(6 years ago) | |
| US7256216 | VIATRIS | Liquid pharmaceutical compositions |
May, 2022
(1 year, 10 months ago) | |
|
US7256216 (Pediatric) | VIATRIS | Liquid pharmaceutical compositions |
Nov, 2022
(1 year, 4 months ago) | |
Drugs and Companies using GABAPENTIN ingredient
Market Authorisation Date: 09 October, 1998
Treatment: NA
Dosage: TABLET;ORAL; SOLUTION;ORAL; CAPSULE;ORAL
NEURONTIN family patents
4. Nitrostat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6500456 | VIATRIS | Compressed nitroglycerin tablet and its method of manufacture |
Sep, 2018
(5 years ago) | |
Drugs and Companies using NITROGLYCERIN ingredient
Market Authorisation Date: 01 May, 2000
Treatment: NA
Dosage: TABLET;SUBLINGUAL
NITROSTAT family patents
5. Revatio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5250534 (Pediatric) | VIATRIS | Pyrazolopyrimidinone antianginal agents |
Sep, 2012
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-287) | Jan 31, 2026 |
| Orphan Drug Exclusivity(ODE-469) | Jan 31, 2030 |
| New Dosing Schedule(D-137) | Jan 31, 2017 |
| M(M-133) | Jan 31, 2017 |
| New Indication(I-598) | May 07, 2012 |
| M(M-61) | Aug 30, 2015 |
| Pediatric Exclusivity(PED) | Nov 07, 2012 |
Drugs and Companies using SILDENAFIL CITRATE ingredient
Market Authorisation Date: 03 June, 2005
Treatment: NA
Dosage: TABLET;ORAL; SOLUTION;INTRAVENOUS
REVATIO family patents
6. Viagra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5250534 (Pediatric) | VIATRIS | Pyrazolopyrimidinone antianginal agents |
Sep, 2012
(11 years ago) | |
| US6469012 | VIATRIS | Pyrazolopyrimidinones for the treatment of impotence |
Oct, 2019
(4 years ago) | |
|
US6469012 (Pediatric) | VIATRIS | Pyrazolopyrimidinones for the treatment of impotence |
Apr, 2020
(4 years ago) | |
Drugs and Companies using SILDENAFIL CITRATE ingredient
Market Authorisation Date: 27 March, 1998
Treatment: Treatment of erectile dysfunction
Dosage: TABLET;ORAL
VIAGRA family patents
7. Zoloft patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5248699 | VIATRIS | Sertraline polymorph |
Aug, 2012
(11 years ago) | |
|
US5248699 (Pediatric) | VIATRIS | Sertraline polymorph |
Feb, 2013
(11 years ago) | |
| US7067555 | VIATRIS | Sertraline oral concentrate |
Oct, 2019
(4 years ago) | |
| US6727283 | VIATRIS | Sertraline oral concentrate |
Oct, 2019
(4 years ago) | |
|
US6727283 (Pediatric) | VIATRIS | Sertraline oral concentrate |
Apr, 2020
(4 years ago) | |
|
US7067555 (Pediatric) | VIATRIS | Sertraline oral concentrate |
Apr, 2020
(4 years ago) | |
Drugs and Companies using SERTRALINE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 March, 1996
Treatment: Treatment of disorders of the serotonergic system such as depression and anxiety-related disorders
Dosage: TABLET;ORAL; CONCENTRATE;ORAL
ZOLOFT family patents